Indo Us Biotech Limited

Indo Us Biotech Limited (INDOUS) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.

Key metrics

Price as of 2026-09-03

Stock price

₹78.82

Market cap

159 Cr

Stock P/E

14.4

P/B

1.71

Dividend yield

0.3%

NSE closing price from historical market data.

Loading price history…

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows

Quarterly · ₹ Cr · tap + rows to expand

Metric	Mar 2021	Mar 2025	Jun 2025	Sept 2025	Dec 2025
Sales	23,24,150 Cr	33 Cr	31 Cr	31 Cr	23 Cr
Operating expenses (approx.)	20,11,430 Cr	29 Cr	25 Cr	27 Cr	19 Cr
EBITDA	3,12,720 Cr	5 Cr	5 Cr	4 Cr	4 Cr
OPM %	13.5%	13.7%	17.8%	13.5%	18.2%
Other income	4,080 Cr	0.12 Cr	0.0015 Cr	0.03 Cr	0.0050 Cr
Interest	63,019 Cr	0.26 Cr	0.45 Cr	0.42 Cr	0.77 Cr
Depreciation	15,718 Cr	0.56 Cr	0.20 Cr	0.21 Cr	0.22 Cr
Profit before tax	2,38,062 Cr	4 Cr	5 Cr	4 Cr	3 Cr
Tax %	-43.6%	5.0%	2.4%	3.0%	5.3%
Net profit	3,41,775 Cr	4 Cr	5 Cr	3 Cr	3 Cr
EPS (₹)	₹5.63	₹1.86	₹2.35	₹1.72	₹1.49

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2021	Mar 2022	Mar 2025	TTM
Sales	40,11,033 Cr	50 Cr	104 Cr	Sign in for TTM
Operating expenses (approx.)	34,78,457 Cr	43 Cr	85 Cr	Sign in for TTM
EBITDA	5,32,575 Cr	7 Cr	19 Cr	Sign in for TTM
OPM %	13.3%	13.5%	18.2%	Sign in for TTM
Other income	4,299 Cr	0.18 Cr	0.18 Cr	Sign in for TTM
Interest	1,16,594 Cr	1 Cr	1 Cr	Sign in for TTM
Depreciation	27,378 Cr	0.46 Cr	1 Cr	Sign in for TTM
Profit before tax	3,92,902 Cr	5 Cr	17 Cr	Sign in for TTM
Tax %	-24.7%	4.7%	1.6%	Sign in for TTM
Net profit	4,89,971 Cr	5 Cr	16 Cr	Sign in for TTM
EPS (₹)	₹8.07	₹8.27	₹8.12	Sign in for TTM
Dividend payout %	—	-3.0%	3.1%	Sign in for TTM

Trailing twelve months totals and margin rows

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2021	Mar 2022	Mar 2025
Equity capital	6,06,799 Cr	9 Cr	20 Cr
Reserves	15,27,403 Cr	29 Cr	58 Cr
Borrowings	10,58,720 Cr	—	15 Cr
Other liabilities	11,77,766 Cr	17 Cr	4 Cr
Total liabilities	43,70,735 Cr	56 Cr	98 Cr
Fixed assets (net)	2,37,035 Cr	8 Cr	10 Cr
CWIP	1,98,577 Cr	—	—
Investments	0 Cr	0 Cr	0 Cr
Loans & advances	1,35,974 Cr	—	0 Cr
Inventories	11,87,965 Cr	23 Cr	71 Cr
Trade receivables	24,70,599 Cr	21 Cr	15 Cr
Cash & bank	13,442 Cr	0.05 Cr	0.25 Cr
Other assets	1,27,141 Cr	4 Cr	2 Cr
Total assets	43,70,735 Cr	56 Cr	98 Cr

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2021	Mar 2022	Mar 2025
Cash from operating activity	—	3 Cr	-1 Cr
Cash from investing	—	5 Cr	-0.79 Cr
Cash from financing	—	5 Cr	-1 Cr
Net cash flow	—	13 Cr	-4 Cr
Free cash flow (OCF − Capex)	—	3 Cr	-1 Cr

Ratios as reported or derived per annual period.

Metric	Mar 2021	Mar 2022	Mar 2025
ROCE %	16.0%	16.8%	19.3%
ROE %	0.0%	13.1%	20.7%
Debtor days	224	149	53
Inventory days	172	3905	363
Days payable	130	—	6
Cash conversion cycle	267	4055	409
Debt / equity	0.50	0.00	0.19
Current ratio	2.10	3.81	5.31
Net debt / EBITDA	1.96	-0.0073	0.77

Loading peers…